Jonathan Lefèbre

ORCID: 0000-0001-8505-2181
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Glycosylation and Glycoproteins Research
  • Monoclonal and Polyclonal Antibodies Research
  • Immunotherapy and Immune Responses
  • RNA Interference and Gene Delivery
  • Advanced Fluorescence Microscopy Techniques
  • RNA regulation and disease
  • Immune Cell Function and Interaction
  • Advanced Biosensing Techniques and Applications
  • Antimicrobial Peptides and Activities
  • RNA and protein synthesis mechanisms
  • Galectins and Cancer Biology
  • Herpesvirus Infections and Treatments

University of Vienna
2022-2025

Max Perutz Labs
2022-2025

Vienna Biocenter
2022-2025

Freie Universität Berlin
2018-2021

Max Planck Institute of Colloids and Interfaces
2021

Single molecule localization-based approaches to super-resolution microscopy (SMLM) create images that resolve features smaller than the diffraction limit of light by rendering them from sequentially measured positions thousands individual molecules. New SMLM based on transient binding very bright dyes via DNA–DNA interaction (DNA-PAINT) allow resolution only a few nanometers apart in vitro. This imaging cellular structures requires specific association their targets, which results an...

10.1088/1361-6463/aae0e2 article EN Journal of Physics D Applied Physics 2018-09-12

C-type lectins are a large superfamily of proteins involved in multitude biological processes. In particular, their involvement immunity and homeostasis has rendered them attractive targets for diverse therapeutic interventions. They share characteristic lectin-like domain whose adaptability enables to bind broad spectrum ligands beyond the originally defined canonical Ca

10.1002/chem.202400660 article EN cc-by Chemistry - A European Journal 2024-03-25

Dendritic cells (DC) are antigen-presenting coordinating the interplay of innate and adaptive immune response. The endocytic C-type lectin receptors DC-SIGN Langerin display expression profiles restricted to distinct DC subtypes have emerged as prime targets for next-generation immunotherapies anti-infectives. Using heteromultivalent liposomes copresenting mannosides bearing aromatic aglycones with natural glycan ligands, we serendipitously discovered striking cooperativity effects DC-SIGN+...

10.1021/jacs.1c07235 article EN cc-by Journal of the American Chemical Society 2021-11-08

Langerin is a mammalian C-type lectin expressed on Langerhans cells in the skin. As an innate immune cell receptor, involved coordinating and adaptive responses against various incoming threats. We have previously reported series of thiazolopyrimidines as murine ligands. Prompted by observation that its human homologue exhibits different binding specificities for these small molecules, we report here our investigations to define their exact site. By using structural comparison molecular...

10.1021/acschembio.2c00626 article EN cc-by ACS Chemical Biology 2022-09-26

Abstract Single molecule localization-based approaches to superresolution microscopy (SMLM) create images that resolve features smaller than the diffraction limit of light by rendering them from sequentially measured positions thousands individual molecules. New SMLM based on transient binding very bright dyes via DNA-DNA interaction (DNA-PAINT) allow resolution only a few nanometers apart in vitro . This imaging cellular structures requires specific association their targets, which results...

10.1101/389445 preprint EN cc-by-nc bioRxiv (Cold Spring Harbor Laboratory) 2018-08-10

DC-SIGN (dendritic cell-specific intercellular adhesion molecule-3-grabbing non-integrin) is a pattern recognition receptor expressed on immune cells and involved in the of carbohydrate signatures present various pathogens, including HIV, Ebola, SARS-CoV-2. Therefore, developing inhibitors blocking carbohydrate-binding site could generate valuable tool to investigate role this several infectious diseases. Herein, we performed fragment-based ligand design using 4-quinolone as scaffold. We...

10.1021/acsmedchemlett.2c00067 article EN ACS Medicinal Chemistry Letters 2022-05-10
Coming Soon ...